ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

Sudan J Paed. 2020; 20(2): 122-125


Neuroblastoma in Sudan: experience of a single institute

Nada Osman Yousif Elhaj, Faisal Abdelgalil Nugud, Omer AbdElhadi Abuagla, Ahmed Abdallah Mohamedani, Huda Mohamed Haroun.



Abstract
Download PDF Post

Neuroblastoma (NBL) is the most common malignant solid extracranial tumour in children. It accounts for about 8%–10% of overall childhood malignancies in developed countries and only 1%–3% in developing countries. We aim to study the clinical presentation and outcome of NBL in children treated at the National Cancer Institute (NCI), University of Gezira, Wad Madani, Sudan. This is a retrospective, descriptive, hospital-based study, where patients’ records were reviewed from the years 2004–2015. During this period, 38 paediatric patients were treated in the Paediatric Oncology Unit at the NCI, accounting for about 4% of the overall childhood malignancies. Of them, 24 (63%) were males and 14 (37%) were females with a ratio of 1.7: 1. The age at presentation ranged between 2 months and 7 years with a mean age at the presentation of 3 years. Twenty-nine (76%) of them were classified as high-risk disease, no one received highdose chemotherapy, 33(87%) died and only 5 (13%) achieved complete remission. This study reflects the poor outcome of NBL among Sudanese children which can be explained by the late presentation of the patients, lack of the diagnostic modalities and lack of the sophisticated treatment modalities for highrisk NBL.

Key words: Neuroblastoma; Child, Outcome; Sudan.







Bibliomed Article Statistics

22
33
40
30
28
33
38
36
38
42
32
23
R
E
A
D
S

11

10

17

15

9

13

8

10

20

15

23

11
D
O
W
N
L
O
A
D
S
040506070809101112010203
20252026

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.